Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2009

View Archived Issues

Novel ligand-directed toxin EGF4KDEL 7mut shows promise in preclinical cancer models

Shire reports results from third quarter of 2009

Phase III data support benefit of mipomersen in homozygous familiar hypercholesterolemia

Aleglitazar has no clinically relevant interactions with statins in healthy subjects

Opioid-nornicotine co-drugs described by the University of Kentucky

CytRx to initiate phase II INNO-206 trial in patients with soft tissue sarcomas

Cytopia begins enrollment in phase I/II trial of CYT-387 in myelofibrosis

Clinical data support safety of mepolizumab in pediatric eosinophilic esophagitis

Gilead Sciences and GSK sign licensing agreement to commercialize Viread for HBV in Asia

Novel dipeptidyl peptidase-IV inhibitors in early development at Sun Pharma

FDA reviews preliminary data from SCOUT safety study of Meridia

Cylene Pharmaceuticals claims novel protein kinase inhibitors for cancer treatment

Nycomed discovers PDE5A inhibitors for the treatment of asthma

Actelion claims P2Y12 receptor antagonists

Transcept to meet with FDA to discuss complete response letter on Intermezzo for insomnia

Accelerate Brain Cancer Cure awards grant to Tocagen to develop treatment for recurrent GBM

Proteon begins phase I/II trial of PRT-201 for improvement of vascular access in ESRD

Ipsen initiates phase II trial of BN-83495 in endometrial cancer

FDA accepts for review Eisai's Aricept NDA for moderate to severe AD

Preclinical characterization of PKI-402 disclosed at AACR-NCI-EORTC meeting

Correlation between high TNFalpha levels and tumor susceptibility to LCL-161

Aegera Therapeutics begins phase IIb AEG-35156 study in acute myeloid leukemia

Astex Therapeutics' AT-9283 is granted orphan drug status in AML in U.S. and Europe

Human Genome Sciences submits BLA to FDA for Zalbin to treat hepatitis C

Merck & Co. and Idera extend research collaboration on TLR agonist vaccine adjuvants

Agensys and Seattle Genetics expand antibody-drug conjugate collaboration